Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Nephrotic syndrome

Efficacy of rituximab in challenging nephrotic syndrome

Nature Reviews Nephrology volume 11, pages 257–258 (2015)Cite this article

Subjects

A new trial provides further evidence that rituximab treatment can reduce the risk of relapse in children with steroid-dependent idiopathic nephrotic syndrome. Addition of a single infusion of rituximab to steroid therapy was associated with a decrease in proteinuria at 3 months and a significant increase in the relapse-free period.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Radhakrishnan, J. & Cattran D. C. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines—application to the individual patient. Kidney Int. 82, 840–856 (2012).

    Article  Google Scholar 

  2. Ravani, P. et al. Rituximab in children with steroid-dependent nephrotic syndrome: a multicentre, open-label, noninferiority, randomized controlled trial. J. Am. Soc. Nephrol. http://dx.doi.org/10.1681/ASN.2014080799 (2015).

  3. Ravani, P. et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin. J. Am. Soc. Nephrol. 6, 1308–1315 (2011).

    Article  CAS  Google Scholar 

  4. Iijima, K. et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter, double-blind, randomized, placebo-controlled trial. Lancet 384, 1273–1281 (2014).

    Article  CAS  Google Scholar 

  5. Fornoni, A. et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci. Transl. Med. 3, 85ra46 (2011).

    Article  Google Scholar 

  6. Filler, G. et al. Should we consider MMF therapy after rituximab for nephrotic syndrome? Pediatr. Nephrol. 26, 1759–1762 (2011).

    Article  Google Scholar 

  7. Faul, C. et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat. Med. 9, 931–938 (2008).

    Article  Google Scholar 

  8. Yu, C. C. et al. Abatacept in B7–1-positive proteinuric kidney disease. N. Engl. J. Med. 369, 2416–2423 (2013).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

R.H.K. is supported by the National Institutes of Health, USA (grant numbers U01DK-03,012 and R24HD050837).

Author information

Authors and Affiliations

  1. Division of Paediatric Nephrology, Children's Hospital Los Angeles, University of Southern California, 4650 Sunset Boulevard, Los Angeles, 90027, CA, USA

    Kevin V. Lemley

  2. Division of Paediatric Nephrology, Rady Children's Hospital, University of California San Diego, 9500 Gilman Drive, La Jolla, 92093-0630, CA, USA

    Robert H. Mak

Authors
  1. Kevin V. Lemley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert H. Mak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert H. Mak.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lemley, K., Mak, R. Efficacy of rituximab in challenging nephrotic syndrome. Nat Rev Nephrol 11, 257–258 (2015). https://doi.org/10.1038/nrneph.2015.26

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2015.26

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing